


POLYOMAVIRUS JC

IgG ANTIBODIES DETECTION BY ELISA

- Diagnostics of diseases associated with polyomavirus JC
- Monitoring of progressive multifocal leukoencephalopathy risk in patients with immunomodulatory therapy (natalizumab)



POLYOMAVIRUS JC


- Diagnostics of diseases associated with polyomavirus JC
- Monitoring of PML risk in patients with immunomodulatory therapy


From 50% to 60% of population is infected by polyomavirus JC (JCV) during childhood. Infection is without any symptoms and later continues to the latent phase, which is characterised by long-term persistence of anamnestic IgG antibodies in serum. Virus can repeatedly reactivate in latently infected people or the reinfection by other serotype can occur. Reactivation/reinfection can be accompanied by temporary viremia or asymptomatic excretion in urine, in rare cases of immunocompromised patients it can cause infection of central nervous system - progressive multifocal leukoencephalopathy (PML). The presence of anti-JCV antibodies is one of the risk factors of PML outbreak in patients treated with natalizumab. Significant increase or high anti-JCV antibody level can indicate reinfection or reactivation in these patients.

Diagnostic efficiency study

The diagnostic efficiency study was performed on 50 serum samples with defined content of anti-JCV antibodies (from National reference laboratory for papillomaviruses and polyomaviruses, Institute of Hematology and Blood Transfusion, Prague, Czech Republic) and 18 serum samples which were parallelly characterised by ELISA-VIDITEST anti-JCV in clinical biochemistry laboratory, University hospital in Ostrava and by validated STRATIFY™ JCV Dx SELECT tests in reference laboratory in Copenhagen and 5 serum samples from transplant recipients with kidney JCV infection proven by DNA in blood and urine.

	Number of samples	ELISA-VIDITEST anti-JCV IgG			
		Positive	Equivocal	Negative	
Anti-JCV IgG negative	28	1	1	26	specificity 96%
Anti-JCV IgG positive	40	37	1	2	sensitivity 95%





POLYOMAVIRUS JC

IgG ANTIBODIES DETECTION BY ELISA

Intended use and testing


ELISA-VIDITEST anti-JCV is ELISA kit for the detection of specific IgG antibodies to JCV in human serum and plasma. ELISA-VIDITEST anti-JCV is easy to use and has high sensitivity and specificity. The kit contains ready to use conjugate and controls and buffers VIDIA, which are interchangeable between VIDIA ELISA kits.

- Samples: serum, plasma
- Quantification using 5 standards
- Incubation times 60'/60'/10'
- Incubation at laboratory temperature
- CE IVD certification

Advantages



- Recombinant antigens do not cross-react with the other polyomaviruses
- Quantitative data evaluation – monitoring of antibody concentration
- High sensitivity 95% and specificity 96%
- Ready to use HRP conjugate and controls
- Interchangeable VIDIA buffers



POLYOMAVIRUS JC

IgG ANTIBODIES DETECTION BY ELISA

Ordering information

Catalogue number	Product	Wells	Sensitivity/specificity
ODZ-450	ELISA-VIDITEST anti-JCV IgG	96	95% / 96%



VIDIA spol. s r.o.
Nad Safinou II 365
252 50 Vestec
Czech Republic

orders@vidia.cz
Tel.: 261 090 565
Fax: 261 090 566
www.vidia.cz

Czech IVD producer



EUROPEAN UNION
European Regional Development Fund
Operational Programme Enterprise
and Innovations for Competitiveness